AstraZeneca Concedes NSCLC Drug Iressa in U.S. Withdrawal
Amid last month's hoopla surrounding AstraZeneca plc's $1.26 billion acquisition of Ardea Biosciences Inc. and CEO David Brennan's decision to step down, the FDA's official withdrawal of lung cancer drug Iressa (gefitinib) was barely a blip on the radar.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST